Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

HemoSphere Alta Study

NCT: NCT07148323 · RECRUITING

NCT IDNCT07148323
StatusRECRUITING
Start Date2025-10-14
Completion2026-12
SponsorBecton, Dickinson and Company (INDUSTRY)
First posted
Last updated

Brief Summary

A prospective, non-randomized single arm study using the HemoSphere Alta Advanced Monitoring Platform and associated devices in adult subjects. Data collected from enrolled study subjects will be used for continual device development purposes.

Frequently Asked Questions

What is HemoSphere Alta Study?

HemoSphere Alta Study is a clinical trial registered under NCT07148323. Current status: RECRUITING.

What is the status of NCT07148323?

The current status of NCT07148323 (HemoSphere Alta Study) is: RECRUITING.

When did HemoSphere Alta Study start?

HemoSphere Alta Study started on 2025-10-14.

Related Devices

K151320BD Phoenix Automated Microbiology System-Ertapenem 0.0625-8 mcg/mlBecton, Dickinson and Company K151589BD MAX CT/GC/TV, BD MAX INSTRUMENTBecton, Dickinson and Company K151866BD BACTEC Peds Plus/F Culture Vials (plastic)Becton, Dickinson and Company K151870BD U-500 INSULIN SYRINGEBecton, Dickinson and Company K153309BD Vacutainer UltraTouch Push Button Blood Collection SetBecton, Dickinson and Company

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑